Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies

Area of Science:

• Immunology
• Neurology
• Oncology

Background:

• Multiple sclerosis (MS) treatments, known as disease-modifying therapies (DMTs), modulate immune responses to reduce inflammation.
• The immune system's role in cancer surveillance suggests that DMT-induced immunosuppression might elevate cancer risk in MS patients.
• Individuals with autoimmune diseases like MS may possess a higher baseline risk for certain cancers, potentially exacerbated by DMTs.

Purpose of the Study:

• To review the molecular mechanisms of current MS DMTs.
• To evaluate the potential of these DMTs in instigating cancer development.
• To explore the therapeutic implications for managing cancer in MS patients.

Main Methods:

• Literature review of existing studies on MS DMTs.
• Analysis of molecular pathways targeted by current MS therapies.
• Examination of the relationship between immunosuppression and oncogenesis in the context of MS.

Main Results:

• Current MS DMTs function by altering immune cell activity, which could inadvertently affect cancer immunosurveillance.
• The combined effects of MS autoimmunity and DMTs present a complex challenge for cancer management.
• There is a lack of established clinical guidelines for treating cancer in MS patients.

Conclusions:

• Understanding the dual role of DMTs in MS and cancer is crucial for patient care.
• Further research is needed to develop specific guidelines for managing comorbid MS and cancer.
• The review highlights the need for a nuanced approach to balancing MS treatment with cancer risk assessment.